GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (NAS:SGMT) » Definitions » Quick Ratio

Sagimet Biosciences (Sagimet Biosciences) Quick Ratio : 43.12 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Sagimet Biosciences's quick ratio for the quarter that ended in Mar. 2024 was 43.12.

Sagimet Biosciences has a quick ratio of 43.12. It generally indicates good short-term financial strength.

The historical rank and industry rank for Sagimet Biosciences's Quick Ratio or its related term are showing as below:

SGMT' s Quick Ratio Range Over the Past 10 Years
Min: 4.04   Med: 18.73   Max: 43.12
Current: 43.12

During the past 5 years, Sagimet Biosciences's highest Quick Ratio was 43.12. The lowest was 4.04. And the median was 18.73.

SGMT's Quick Ratio is ranked better than
97.87% of 1551 companies
in the Biotechnology industry
Industry Median: 3.53 vs SGMT: 43.12

Sagimet Biosciences Quick Ratio Historical Data

The historical data trend for Sagimet Biosciences's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagimet Biosciences Quick Ratio Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
5.21 35.99 24.04 6.21 17.09

Sagimet Biosciences Quarterly Data
Dec19 Mar20 Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.12 4.04 20.36 17.09 43.12

Competitive Comparison of Sagimet Biosciences's Quick Ratio

For the Biotechnology subindustry, Sagimet Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sagimet Biosciences's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's Quick Ratio falls into.



Sagimet Biosciences Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Sagimet Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(96.646-0)/5.654
=17.09

Sagimet Biosciences's Quick Ratio for the quarter that ended in Mar. 2024 is calculated as

Quick Ratio (Q: Mar. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(194.491-0)/4.51
=43.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sagimet Biosciences  (NAS:SGMT) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Sagimet Biosciences Quick Ratio Related Terms

Thank you for viewing the detailed overview of Sagimet Biosciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sagimet Biosciences (Sagimet Biosciences) Business Description

Traded in Other Exchanges
Address
155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
Executives
David Happel director, officer: President & CEO 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Beth C Seidenberg director
Nea 13 Gp, Ltd 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Elizabeth Rozek officer: General Counsel and CCO SAGIMET BIOSCIENCES INC., 155 BOVET ROAD, SUITE 303, SAN MATEO CA 94402
George Kemble director SAGIMET BIOSCIENCES INC., 155 BOVET RD., STE. 303, SAN MATEO CA 94402
Jinzi Jason Wu director SAGIMET BIOSCIENCES INC., 155 BOVET RD., SUITE 303, SAN MATEO CA 94402
Dennis Hom officer: Chief Financial Officer C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Kpcb Pbd Associates, Llc 10 percent owner C/O KLEINER PERKINS CAUFIELD & BYERS, 2750 SAND HILL ROAD, MENLO PARK CA 94025
Kpcb Pandemic & Bio Defense Fund Llc 10 percent owner 2750 SAND HILL RD, MENLO PARK CA 94025
Eduardo Bruno Martins director 350 CAMBRIDGE AVE, SUITE 350, PALO ALTO CA 94306
Nea Partners 13, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Elizabeth A Grammer director 78TH FOURTH AVENUE, WALTHAM MA 02451
Anthony M Rimac officer: Chief Operating Officer C/O ADAMAS PHARMACEUTICALS, INC., 2200 POWELL ST, STE 220, EMERYVILLE CA 94608
Patrick J Kerins 10 percent owner